drugset / Trial / NCT06046820
The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of Study INZ701-106 (The ENERGY 3 Study) is to assess the efficacy and safety of INZ-701 in children with ENPP1 Deficiency.
Timeline
- Start
- 2023-11-05
- Primary completion
- 2026-01-29
- Completion
- 2026-08-19
Outcome
Outcome not reported
Stopped: “The study was terminated by the sponsor prior to planned completion based on a review of the data across indications and overall program considerations. Study termination was not related to participant safety.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | INZ-701 | Protein / enzyme biologic | 1.8 mg/kg | Subcutaneous |
| Subject | INZ-701 | Protein / enzyme biologic | 2.4 mg/kg | Subcutaneous |
| Comparator | Calcitriol | Small molecule | — | Oral |